ATAqila Taqi

Aqila Taqi

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article

Previous Organizations / Institutes

The organizations / institutes from the scholar's other articles in the past ten years


Aqila Taqi has a total of 27 co-authors. Here are the top co-authors by number of shared publications:


Latest Publications

  • Open Access

    The Effectiveness of Respiratory Syncytial Virus Prophylaxis Programme using Palivizumab in Preterm Infants: A single institute retrospective study

    by Hilal Al Mandhari, Saif Al Kendi, Noura Al-Balushi, Aqeela Bintaqi, Abdulrahman Al Saadi, Mohamed Abdellatif

    Objectives: This study aimed to evaluate the effectiveness of an established respiratory syncytial virus (RSV) prophylaxis programme by assessing RSV-related hospitalisations (RSVH) and identify associated risk factors among preterm infants born at <32 weeks’ gestation. Methods: This retrospective cohort study was conducted at Sultan Qaboos University Hospital, Muscat, Oman. Eligible participants were preterm infants <32 weeks’ gestation, born between January 2015 and December 2020, who received RSV prophylaxis. Data were extracted from electronic medical records and analysed. Results: A total of 282 infants were included. The mean gestational age was 28.56 ± 2.03 weeks and the mean birth weight was 1.23 ± 0.35 kg. A total of 5 infants (1.8%) experienced RSV-related hospitalisation while receiving palivizumab prophylaxis. Infants with RSVH were significantly more likely to be born at <28 weeks’ gestation than those who had not had a RSVH (60% versus 26.7%; P = 0.033). The rate of bronchopulmonary dysplasia was significantly higher in RSVH infants compared to those without RSVH (60% versus 14.1%; P = 0.026). Conclusion: The RSV prophylaxis programme demonstrated effectiveness, with a low RSVH rate among high-risk preterm infants. Extreme prematurity and bronchopulmonary dysplasia are the most significant risk factors for RSVH. Despite being a single-centre retrospective study, this is the first evaluation of RSV immunoprophylaxis in Oman and supports the case for a nationwide programme targeting high-risk infants.

  • Open Access

    Patterns of analgesic utilisation among people with knee osteoarthritis: a cohort study using UK primary care data

    by Aqila Taqi, Sonia Gran, Roger David Knaggs

    Osteoarthritis (OA) is a prevalent disabling joint disease affecting more than 300 million people globally and knees are most commonly affected. It is associated with pain and functional limitation that adversely affect mental well-being and compromise quality of life. Analgesic use is common among patients with knee osteoarthritis (KOA), however, data on patterns of analgesics use at an individual patient level are sparse. The present study describes patterns of analgesic use, by determining the proportion of persistent users within one year of therapy initiation in patients with KOA. A retrospective cohort study using the clinical practice research datalink. Analgesic prescriptions for adults with an incident KOA diagnosis were captured and grouped into five exposure groups including: antidepressants, antiepileptic drugs (AEDs), opioids, non-steroidal anti-inflammatory drugs (NSAIDs) and paracetamol. A persistent user was a person who used >180 defined daily doses (DDDs) per year and had prescriptions in at least three out of the four quarters of the year. Variable proportions of patients used respective analgesic classes persistently during the first year after prescribing; 36.8% of antidepressant users, 27.0% of NSAIDs, 23.8% of AEDs, 17.5% of paracetamol and 14.9% of opioid users were persistent users. Across classes, persistent users were slightly younger, were issued more prescriptions and used higher doses of analgesics compared to non-persistent users. Between 14.9% and 36.8% became persistent analgesic users by the end of the first year after their initial prescription. The study applied meaningful clinical attributes to define persistence. This informs future research on clinical and adverse drug outcomes in persistent users compared to non-persistent users across five separate analgesic classes.


  • Open Access

    “Application of five different strategies to define a cohort of patients with knee osteoarthritis in a large primary care database”

    by Aqila Taqi, Sonia Gran, Roger David Knaggs

    Background: Electronic health records (EHR) are frequently used for epidemiological research including drug utilisation studies in a defined population such as the population with knee osteoarthritis (KOA). We sought to describe the process of defining a cohort of patients with KOA from a large UK primary care database and estimate the annual incidence of diagnosed KOA between 2000 and 2015.Method: This was a retrospective study using data from the clinical practice research datalink (CPRD). CPRD is a large primary care longitudinal electronic medical records’ database that contains anonymous records of patients from general practices across United Kingdom. Five different cohort definition strategies were applied including symptoms‐based or diagnosis‐based strategies or a combination of both. To validate results, the annual incidence of KOA was estimated and compared to published data.Results: The study defined 898,690 patients when symptoms‐based strategy was applied, 137,541 patients when diagnosis based and 83,294 when a combination of both strategies were applied. The final cohort was defined using a diagnosis‐based strategy that avoided overestimation (with symptoms‐based definition) or underestimation (with a combination of symptoms and diagnosis). The incidence of KOA ranged from 1.33 per 1000 CPRD registrants in 2000, 1.76 in 2008 and 1.45 patients in 2015.Conclusion: This study logically/sensibly defined a cohort of patients with diagnosed KOA through the application of several strategies. This was an essential step to avoid subsequent over or underestimation of the prevalence of drug utilisation and the associated adverse clinical outcomes within primary care patients with KAO.


  • Open Access

    Analgesic utilization in people with knee osteoarthritis: A population‐based study using primary care data

    by Aqila Taqi, Sonia Gran, Roger D. Knaggs

    PurposeOsteoarthritis (OA) is a chronic painful condition that often affects large joints such as the knee. Treatment guidelines recommend paracetamol, nonsteroidal anti-inflammatory drugs (NSAIDs), and opioids. Antidepressants and anti-epileptic drugs (AEDs) are commonly prescribed for chronic noncancer pain conditions including OA, as an off-label use. This study describes analgesic utilization in patients with knee OA at population level using standard pharmaco-epidemiological methods. MethodThis was a cross-sectional study between 2000 and 2014 using data from the U.K. Clinical Practice Research Datalink (CPRD). The use of antidepressants, AEDs, opioids, NSAIDs, and paracetamol was studied in adults with knee OA using the following measures: annual number of prescriptions, defined daily doses (DDD), oral morphine equivalent dose (OMEQ), and days' supply. ResultsIn total, there were 8,944,381 prescriptions prescribed for 117,637 patients with knee OA during the 15-year period. There was a steady increase in the prescribing of all drug classes, except for NSAIDs, over the study period. Opioids were the most prevalent class prescribed in every study year. Tramadol was the most commonly prescribed opioid, with the number of DDD increasing from 0.11 to 0.71 DDDs per 1000 registrants in 2000 and 2014, respectively. The largest increase in prescribing was for AEDs, where the number of prescriptions increased from 2 to 11 per 1000 CPRD registrants. ConclusionThere was an overall increase in the prescribing of analgesics apart from NSAIDs. Opioids were the most frequently prescribed class; however, the greatest increase in prescribing between 2000 and 2014 was observed in AEDs.


  • Open Access

    The Impacts of Clinical Pharmacists’ Interventions on Clinical Significance and Cost Avoidance in a Tertiary Care University Hospital in Oman: A Retrospective Analysis

    by Juhaina Salim Al-Maqbali, Aqila Taqi, Samyia Al-Ajmi, Buthaina Al-Hamadani, Farhat Al-Hamadani, Fatima Bahram, Kifah Al-Balushi, Sarah Gamal, Esra Al-Lawati, Bushra Al Siyabi, et al.

    Objectives: Pharmaceutical interventions are implicit components of the enhanced role that clinical pharmacists provide in clinical settings. We aimed to study the clinical significance and analyze the presumed cost avoidance achieved by clinical pharmacists’ interventions. Methods: A retrospective study of documented clinical pharmacists’ interventions at a tertiary care hospital in Oman was conducted between January and March 2022. The interventions were electronically recorded in the patients’ medical records as routine practice by clinical pharmacists. Data on clinical outcomes were extracted and analyzed. Cost implications were cross checked by another clinical pharmacist, and then, cost avoidance was calculated using the Rx Medi-Trend system values. Results: A total of 2032 interventions were analyzed, and 97% of them were accepted by the treating physicians. Around 30% of the accepted interventions were for antimicrobials, and the most common type was dosage adjustment (30%). Treatment efficacy was enhanced in 60% and toxicity was avoided in 22% of the interventions. The presumed cost avoided during the study period was USD 110,000 with a projected annual cost avoidance of approximately USD 440,000. Conclusion: There was an overall positive clinical and financial impact of clinical pharmacists’ interventions. Most interventions have prevented moderate or major harm with a high physician acceptance rate. Optimal documentation of the interventions is crucial for emphasizing clinical pharmacists’ value in multi-specialty hospitals.


  • Open Access

    Levels of agreement among clinical pharmacists on the impact of pharmaceutical interventions in Oman: A retrospective analysis

    by Juhaina Salim Al-Maqbali, Aqila Taqi, Buthaina Al-Hamadani, Sara Gamal, Esra Al-Lawati, Najwa Al Himali, Fatima Bahram, Suad Al-Jabri, Nashwa Al-Sharji, Saud Homood, et al.

    Objectives: Disagreement between health care providers on medication-related interventions can affect clinical outcomes. We aimed to study the outcomes and significance of clinical pharmacists’ interventions and evaluate the levels of agreement between different clinical pharmacists on the impact of pharmaceutical interventions. Methodology: A retrospective study was conducted at a tertiary care hospital in Oman. The study included all documented interventions by clinical pharmacists for all categories of admitted patients that met the inclusion criteria. Results: The originator clinical pharmacists interjected to improve the efficacy of treatment in (58%, n=1740) of the interventions, followed by toxicity reduction (24%). The level of agreement in the clinical significance resulted in substantial Scotts’ kappa (k) between the originator and the first reviewer, the first and second reviewers, and the second reviewer and supervisor (86%; k=0.77; P<.001), (77%; k=0.63; P<.001), (84%; k=0.77; P<.001), respectively. In terms of grading of clinical significance, the originator clinical pharmacists recorded moderate significance in 50% of the interventions, followed by major (30%), not applicable (8.4%), and minor (7.3%). The level of agreement in the clinical significance resulted in substantial Scotts’ k between the originator and the first reviewer, and between the second reviewer and supervisor (82%; k=0.72; P<.001), (84%; k=0.77; P<.001), respectively. The level of agreement between the first and second reviewer was fair (55%; k=0.28; p<0.001). Conclusion: Clinical pharmacists’ interventions have a crucial impact on patient safety, improving efficacy and reducing toxicities. Overall, there was a substantial agreement among clinical pharmacists on the clinical significance and grading of the interventions.. Pharmacy Practice is a free full-text journal with a scope on the practice of pharmacy. Pharmacy Practice covers pharmaceutical care, social pharmacy, pharmacy education, process and outcome research, health promotion and education, health informatics, pharmacoepidemiology